As device therapy continues to evolve, there is an emerging opportunity to address tricuspid valve disease in patients who previously were overlooked due to their high surgical risk. Proper patient selection and medical optimization will be critical factors driving the success or failure of these nascent technologies.

In this interview, Sean Pinney, MD, FACC, FAST, FHFSA, and Sidney C. Smith Jr., MD, MACC, discuss Optimal Medical Therapy for Tricuspid Regurgitation: An Oxymoron?.

Related References:

1. Sanz J et al. J Am Coll Cardiol 2019;73:1463–82
2. Taramasso M, et al. J Am Coll Cardiol Img 2019;12:605–21

Clinical Topics: Arrhythmias and Clinical EP, Dyslipidemia, Valvular Heart Disease

Keywords: ACCELLite, Tricuspid Valve

< Back to Listings